u/kvmcc · 256d agono track record yet
$PSTV - Why I’m holding through 2026. This isn't your typical "hope and pray" biotech
Plus Therapeutics has a revenue-generating diagnostic product (CNSide) already deployed at 120+ cancer centers with major payer coverage, plus a high-upside catalyst in REYOBIQ, a liquid radiation therapy with constructive FDA feedback. Insider buying, institutional accumulation, and analyst target of $7.25 on a $0.55 stock suggest substantial upside potential over the next two years.
Now $3.87as of Sep 17, 4:30 PM ET